obesity drug news today glp-1 october 27 2025 Pipeline Update: May - Prime Therapeutics Beyond GLP-1: the next wave

For example, different actions of GLP-1 receptor agonists such as delaying gastric emptying which leads to a prolonged feeling of fullness and reducing food intake lead to significant weight loss ( Endogenous GLP-1 has a short half-life since it is in 1-2 minutes degraded by the enzyme dipeptidyl peptidase-4 (DPP-4)

Introduction Diabetes mellitus (DM) is a complex, chronic illness requiring continuous medical care with multifactorial risk-reduction strategies in order to reduce complications

Available from: Linderoth PM (2024) Efter felaktig frskrivning av diabeteslkemedel anmlan till Ivo

exposure groups might have been misaligned on important baseline characteristics, potentially leading to confounding

In summary, GLP-1 RAs represent a promising therapeutic option for obese patients with HFpEF, but their large-scale adoption will require further evidence of efficacy, safety, and long-term benefits through rigorous and well-designed clinical trials

Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting akt activation